PreeclampsiaScreen™ I T1 can enhance the detection rate of your current screening protocol.

60%Biochemistry
+ History

77%Biochemistry
+ History
+ MAP

91%Biochemistry
+ History
+ MAP + UtAD-PI

Increase Your Vigilance,
Guide Your Treatment.

Combined with two biophysical markers, PreeclampsiaScreen™ | T1 can greatly increase your ability to detect patient risk for early onset preeclampsia.

Early Onset Preeclampsia: A Clinical Dilemma

Early onset preeclampsia is defined as preeclampsia resulting in the delivery of the fetus before 34 weeks' gestation. It is estimated to occur in approximately 0.5% of all pregnancies. Early onset preeclampsia is less common than the late form of the disorder, but contributes more to the morbidity and mortality of pregnant mothers and babies.

Possible early intervention options for preeclampsia include increased monitoring, modified activity, bed rest and medications, including aspirin. To date, there has been no reliable way to detect early onset preeclampsia, particularly for patients experiencing their first pregnancy. Therefore, there has been no satisfactory method with which to stratify patients at high risk of early onset preeclampsia from those at lower risk. Until now.

PreeclampsiaScreen™ | T1.
The Power to Know Sooner.

PreeclampsiaScreen™ | T1 is the first screening test in the U.S. to measure three biochemical markers in the mother's serum associated with preeclampsia: PAPP-A (pregnancy-associated plasma protein-A); PlGF (placental growth factor) and AFP (alpha fetoprotein). Together, these three biochemical markers can contribute to accurate prediction of risk for early onset preeclampsia.

The Benefits:

PreeclampsiaScreen™ | T1 enables accurate detection of early onset preeclampsia risk, allowing for earlier intervention and management of the pregnancy.

Earlier Prediction for Earlier Intervention.

Early detection of early onset preeclampsia allows a valuable window of opportunity for vigilance and intervention. First trimester identification of risk for preeclampsia enables:

Test Specifications for Early Onset Preeclampsia, Combinations of Markers + History

*False positive rates are representative of a general screening population. Rates may vary depending on history. Risk cutoff in each case is 1 in 50.

(References 36-52)

DISCLAIMER: This test is a part of a lab service offering provided by Eurofins NTD, LLC. This test was developed and its performance characteristics determined by Eurofins NTD, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. The methods and performance characteristics have been reviewed and approved by the New York State Department of Health. The test results do not eliminate the possibility that this pregnancy may be associated with birth defects or pregnancy complications including preeclampsia, pre-term delivery and low birth weight. The multiple of the median and risk results provided in the test report are dependent on the accuracy of the demographic and ultrasound information provided. The ordering physician should ensure that the ultrasound information has been obtained from a sonographer who is credentialed by and participating in a uterine artery Doppler quality review program such as FMF. Eurofins NTD, LLC. assumes no responsibility for ensuring that the ultrasound information has been obtained by a properly credentialed sonographer, including verification or updates to credentialing status.